20th Biosimilar Medicines Conference

Topics

• Biosimilars: the European Commission industrial policy strategy and "Tajani initiative" follow-up
• Biological and biosimilar medicines market: current status and future outlook
• Biosimilars uptake: best practice sharing by key EU member states
• Biosimilars evolving landscape: insight into market access
• Real World Evidence sharing
• Debate on GfK study findings: a multi-stakeholder approach in support of the biosimilar medicines market sustainability
• Biosimilars naming and labelling regime: the European experience
• The science of extrapolation of indications, explained by EU regulators
• Biosimilar medicines approvals and scientific guidelines latest developments: the EMA overview
• WHO Biological Qualifier Scheme: status of the proposal
• Biosimilars: news from the US/FDA
• Biosimilars global development: the role of WHO and National Drug Regulatory Authorities
• The biosimilarity concept: bringing it closer to patients, healthcare professionals and medical societies

Who should Attend

International Regulators, leading EU and Experienced EU Companies.